Advaxis, Inc. Risk Report
Explore Advaxis, Inc. across six non‑financial risk dimensions:ESG, Workforce, News & Media, Cybersecurity, Legal & Regulatory, Operational. Unlock the full report, original sources and timelines, and enable continuous monitoring.
Summary
🛡️ Financial & Liquidity
Advaxis, Inc. has experienced significant financial changes and acquisitions in recent years. OS Therapies' acquisition of key assets from Advaxis, completed in 2025, marks a pivotal rearrangement of Advaxis' financial landscape. Previously in 2023, Advaxis merged with Ayala Pharmaceuticals, further solidifying their strategic position in the market. The volatility of Advaxis' financial operations has been evident through these major transactions, reflecting on their adaptive business strategy amid financial risks.
- OS Therapies completed the acquisition of Advaxis immunotherapies clinical, pre-clinical, and IP assets from Ayala Pharmaceuticals 🗓 April 9, 2025.
- Advaxis and Ayala Pharmaceuticals completed their merger 🗓 January 19, 2023.
- Ayala Pharmaceuticals and Advaxis agreed to combine, with expectations of uplisting on Nasdaq 🗓 October 19, 2022.
- Advaxis Inc. shares surged past their previous 52-week high, indicating market movement 🗓 January 16, 2022.
⚖️ Legal & Regulatory
There have been legal developments surrounding Advaxis, mainly focusing on their merger activities. The merging and acquisition processes with Ayala Pharmaceuticals have positioned the company within a complex regulatory landscape, requiring compliance with legal frameworks. This highlights their ability to manage legal challenges inherent in significant corporate restructurings.
- Morgan Lewis advised Advaxis in the Ayala Pharmaceuticals merger 🗓 October 19, 2022.
- Ayala Pharmaceuticals announced the closing of a merger with Biosight, a move impacting Advaxis 🗓 October 19, 2023.
👥 Labor & Workforce
Operational strategies within Advaxis have led to workforce adjustments to align business goals with economic realities. The company's strategic decisions have occasionally impacted their workforce, notably through layoffs linked to business pivots towards their cancer pipeline.
- Advaxis laid off staff as part of a strategy to refocus their cancer pipeline 🗓 June 8, 2018.
📜 Innovation & R&D
Innovation and research continue to be at the forefront of Advaxis' strategic operations, demonstrating a focused effort on advancing their oncological pipeline. Their collaborations and study completions underscore their role in the biotechnology sector, specifically aiming at vaccines and immune therapies as significant innovations.
- Advaxis announced publication of ADXS-PSA data in The Oncologist, reflecting continued innovation in their cancer research 🗓 April 8, 2022.
- Advaxis began a Phase 3 study of its Axal vaccine for advanced cervical cancer 🗓 November 9, 2016.
Profile
News & Media
Real‑time aggregation of trusted sources tracking company‑related events with sentiment and topic tags for rapid risk triage.
Sign up to unlock Advaxis, Inc.’s complete news feed with sentiment and topic tags.
View Full ReportEntity List
Continuous third‑party screening across global sanctions, enforcement, and watchlist sources with unified entity resolution and real‑time alerts.
| Name | Issuer | Status |
|---|---|---|
| ACF List of War Enablers | Anti-Corruption Foundation | |
| African Development Bank Debarred Entities | African Development Bank Group | |
| Argentina Members of Parliament | Honorable Cámara de Diputados de la Nación Argentina | |
| Argentina RePET Sanctions | Ministerio de Justicia | |
| Armenia Public Officials and Associates | Hetq Online | |
| Asian Development Bank Sanctions | Asian Development Bank | |
| Australian Sanctions Consolidated List | Department of Foreign Affairs and Trade | |
| Democratic People's Republic Of Korea (North Korea) Sanctions Regime | Department of Foreign Affairs and Trade | |
| Former Federal Republic Of Yugoslavia Sanctions Regime | Department of Foreign Affairs and Trade | |
| Iran Sanctions Regime | Department of Foreign Affairs and Trade |
Sign up to unlock Advaxis, Inc.’s sanctions, enforcement, and watchlist risk profile.
View Full ReportESG
Verification of declared ESG commitments and certifications with evidence links, score signals, and status updates across E, S, and G.
| Name | Status |
|---|---|
| Sustainable Finance Disclosure Regulation | |
| Global Reporting Initiative Standards | |
| EU Taxonomy Regulation | |
| EU Corporate Sustainability Reporting Directive | |
| California Transparency in Supply Chains Act | |
| EU Non-Financial Reporting Directive | |
| ISO 14001 | |
| Sustainability Accounting Standards Board Standards | |
| Task Force on Climate-related Financial Disclosures | |
| UN Guiding Principles on Business and Human Rights |
Sign up to unlock Advaxis, Inc.’s ESG commitments, certifications, and controversy signals.
View Full ReportCybersecurity
Verification of adherence to recognized security standards, mapping control coverage and gaps affecting third‑party and supply‑chain risk.
| Certification | Status |
|---|---|
| General Data Protection Regulation | |
| Digital Operational Resilience Act | |
| Cybersecurity Maturity Model Certification | |
| NIST Cybersecurity Framework | |
| NIST 800-53 Revision 5 | |
| California Consumer Privacy Act | |
| ISO/IEC 27001 | |
| Health Insurance Portability and Accountability Act | |
| Payment Card Industry Data Security Standard | |
| Federal Information Security Modernization Act |
Sign up to unlock Advaxis, Inc.’s security standards, control gaps, and exposure risks.
View Full ReportGet Advaxis, Inc.'s full Non-Financial Risk Report
By signing up, you agree to our Terms and Privacy Policy.